

Peer review comments – Azithromycin

Managing COVID-19 rapid guideline (NG191)

Peer review organisations

For a list of stakeholders invited to comment on COVID-19 guidance as part of the targeted peer review, please see the [targeted peer review stakeholder list](#) on the NICE website.

For this topic, the following stakeholder organisations were also invited to comment:

- Royal College of Pathologists

Overarching category	Guideline section	Theme of comments	Action taken
General comments	Recommendation	All peer reviewers were in agreement with the recommendation or had no comments to make.	No action necessary
Pregnancy	Evidence to decision - Equity	RCOG suggested that we use advice from their guideline rather than the manufacturers advice for azithromycin use in pregnancy. The manufacturers advice is to only give azithromycin in pregnancy where no alternative is available (for licensed indications). RCOG advice is the same as our do not offer recommendation.	We have removed the statement around the manufacturers advice but have not replaced. This is because it does not saying anything different to our recommendation.
Pregnancy	Evidence summary	The same comment regarding RCOG advice was made in the evidence summary where we state that “pregnant women were excluded from the trials”.	No action necessary as this is just a summary of the evidence.
Children	General	RCPCH noted that the recommendations were based on adult data only. However, they agree with the recommendation unless new	No action necessary

Date of completion: 18/05/2021

	evidence suggests otherwise. They also inform us that the paediatric data from azithromycin arm of RECOVERY has not been published yet.	
--	---	--